|
|
Other links at Articles > Allergy and Clinical Immunology |
| 3. |
FDA Approvals: Moxatag, Welchol, Sular
|
|
|
The FDA has approved amoxicillin extended-release tablets (Moxatag), a new indication for colesevelam tablets (Welchol), and newly formulated nisoldipine extended-release tablets (Sular). Medscape Medical News
|
| 4. |
Omalizumab Not Cost Effective for Severe Asthma
|
|
|
Omalizumab is not a cost-effective treatment for most patients with severe asthma, according to an analysis presented in the November Journal of Allergy and Clinical Immunology. Reuters Health Information
|
|
|